Tumor localization may change the type of adjuvant treatment in gastric cancer.
- Published in:
- 2017
- By:
- Publication type:
- Letter
Works matching AU Altundag, Kadri
Results: 277
1
2
Is there a role of breast pathologist in diagnostic challenges of discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis?
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
3
Prognostic effect of neutrophil-lymphocyte ratio during concurrrent chemo-radiotherapy period in glioblastoma patients who did not receive dexamethasone.
- Published in:
- 2018
- By:
- Publication type:
- Letter
4
Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?
- Published in:
- 2017
- By:
- Publication type:
- Letter
5
Tumor types, breast tumor subtypes and extension of systemic disease may influence outcome in cancer patients with brain metastases.
- Published in:
- 2017
- By:
- Publication type:
- Letter
6
Radio-sensitising effect of T-DM1 should not be discarded for the efficacy of radiosurgery in the management of brain metastases in patients with HER2-positive metastatic breast cancer.
- Published in:
- 2017
- By:
- Publication type:
- Letter
7
Prognostic factors in breast cancer patients with brain metastases.
- Published in:
- Journal of Neuro-Oncology, 2008, v. 87, n. 2, p. 193, doi. 10.1007/s11060-007-9506-0
- By:
- Publication type:
- Article
8
Safety Analysis of Premenopausal Breast Cancer Patients in PALOMA-3 Study: Is It Worth Mentioning?
- Published in:
- 2017
- By:
- Publication type:
- Letter to the Editor
9
The Prevalence of Systemic Rheumatic Diseases Among Breast Cancer Patients and Its Relationship With Survival.
- Published in:
- Archives of Rheumatology, 2019, v. 34, n. 2, p. 141, doi. 10.5606/ArchRheumatol.2019.6803
- By:
- Publication type:
- Article
10
PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.
- Published in:
- 2024
- By:
- Publication type:
- Letter
11
Clinical research on triple-negative breast cancer that targets the PIK3CA pathway.
- Published in:
- 2024
- By:
- Publication type:
- Letter
12
Which drug would be more effective in treating patients with leptomeningeal metastases from breast cancer: intrathecal thiotepa or methotrexate?
- Published in:
- 2024
- By:
- Publication type:
- Letter
13
Benefits of capecitabine in hormone receptor-positive compared to hormone receptor‐negative HER2 normal metastatic breast cancer.
- Published in:
- 2024
- By:
- Publication type:
- Letter
14
Hormone/HER2 receptor crosstalk in breast cancer needs further investigation.
- Published in:
- 2024
- By:
- Publication type:
- Letter
15
The use of pentoxifylline might enhance the effect of chemotherapy or radiotherapy in reducing tumor growth.
- Published in:
- 2023
- By:
- Publication type:
- Letter
16
Taxane use in breast cancer and risk of brain metastases.
- Published in:
- 2018
- By:
- Publication type:
- Letter
17
More predictive markers were identified for trastuzumab-induced cardiotoxicity.
- Published in:
- 2018
- By:
- Publication type:
- Letter
18
Why do younger breast cancer patients with blood group O have favorable prognosis?
- Published in:
- 2017
- By:
- Publication type:
- Letter
19
Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma.
- Published in:
- European Journal of Haematology, 1997, v. 59, n. 2, p. 100, doi. 10.1111/j.1600-0609.1997.tb00732.x
- By:
- Publication type:
- Article
20
Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients.
- Published in:
- 2025
- By:
- Publication type:
- Letter
21
Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?
- Published in:
- 2024
- By:
- Publication type:
- Letter
22
Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density.
- Published in:
- 2024
- By:
- Publication type:
- Letter
23
Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients.
- Published in:
- 2024
- By:
- Publication type:
- Letter
24
Are breast cancer subtypes different in breast cancer patients with and without hepatitis C virus infection?
- Published in:
- 2024
- By:
- Publication type:
- Letter
25
Younger breast cancer patients under the age of 35 might have a better disease-free survival if they received ovarian function suppression more than 3 years.
- Published in:
- Breast Cancer (13406868), 2019, v. 26, n. 2, p. 263, doi. 10.1007/s12282-018-0897-x
- By:
- Publication type:
- Article
26
Questions about lower inner zone tumors in early-stage breast cancer.
- Published in:
- 2017
- By:
- Publication type:
- Letter
27
Pure invasive lobular carcinoma versus mixed invasive lobular cancer and invasive ductal carcinoma: metastatic patterns differ?
- Published in:
- 2017
- By:
- Publication type:
- Letter
28
Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer.
- Published in:
- 2017
- By:
- Publication type:
- Letter
29
Does longer disease-free interval affect the complete remission in metastatic breast cancer?
- Published in:
- 2017
- By:
- Publication type:
- Letter
30
Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG).
- Published in:
- Breast Cancer (13406868), 2015, v. 22, n. 5, p. 480, doi. 10.1007/s12282-013-0506-y
- By:
- Publication type:
- Article
31
Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'.
- Published in:
- British Journal of Cancer, 2017, v. 116, n. 8, p. e10, doi. 10.1038/bjc.2017.60
- By:
- Publication type:
- Article
32
Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'.
- Published in:
- 2017
- By:
- Publication type:
- Letter
33
An Unusual Case of Metastatic Rectal Carcinoma Presenting as Thyroid Nodule.
- Published in:
- 2000
- By:
- Publication type:
- Letter
34
Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
- Published in:
- Journal of Surgical Oncology, 2000, v. 73, n. 1, p. 12, doi. 10.1002/(sici)1096-9098(200001)73:1<12::aid-jso4>3.3.co;2-b
- By:
- Publication type:
- Article
35
Use of scalp cooling therapy in patients with breast or gynecological cancers undergoing chemotherapy may be associated with a higher risk of systemic recurrence.
- Published in:
- 2025
- By:
- Publication type:
- Letter
36
Probable association between increased systemic recurrence and the use of scalp cooling in breast cancer patients receiving (neo)adjuvant chemotherapy.
- Published in:
- 2021
- By:
- Publication type:
- Letter
37
Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors?
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
38
Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors?
- Published in:
- 2018
- By:
- Publication type:
- journal article
39
Administrating docetaxel, doxorubicin, and cyclophosphamide as a neoadjuvant treatment may decrease lymphedema risk in breast cancer patients.
- Published in:
- 2018
- By:
- Publication type:
- Letter
40
Patients' understanding of treatment goals and disease course and their relationship with optimism, hope, and quality of life: a preliminary study among advanced breast cancer outpatients before receiving palliative treatment.
- Published in:
- 2016
- By:
- Publication type:
- journal article
41
Zoledronic acid and atrial fibrillation in cancer patients.
- Published in:
- 2011
- By:
- Publication type:
- journal article
42
Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole: a case report.
- Published in:
- European Journal of Clinical Pharmacology, 2004, v. 60, n. 6, p. 455, doi. 10.1007/s00228-004-0790-8
- By:
- Publication type:
- Article
43
Possible association between Budd‐Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia.
- Published in:
- American Journal of Hematology, 2005, v. 80, n. 3, p. 213, doi. 10.1002/ajh.20432
- By:
- Publication type:
- Article
44
Modified ESHAP as Salvage Chemotherapy for Recurrent or Refractory Non-Hodgkin's Lymphoma: Results of a Single-Center Study of 32 Patients.
- Published in:
- Chemotherapy (0009-3157), 2002, v. 48, n. 5, p. 252, doi. 10.1159/000066768
- By:
- Publication type:
- Article
45
REAL-LIFE USE AND DECISION IMPACT OF MAMMAPRINT ON CLINICAL PRACTICE IN EARLY BREAST CANCER: A MULTICENTER TURKISH ONCOLOGY GROUP STUDY.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
46
Recent Findings for Anti-Metastatic Potential of Heparin.
- Published in:
- 2006
- By:
- Publication type:
- Letter
47
Clinicopathological analysis of 38 male patients diagnosed with breast cancer.
- Published in:
- Breast Disease, 2024, v. 43, p. 1, doi. 10.3233/BD-230050
- By:
- Publication type:
- Article
48
Trastuzumab in metastatic breast cancer after complete remission: How long is enough?
- Published in:
- 2015
- By:
- Publication type:
- Letter
49
Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer.
- Published in:
- 2014
- By:
- Publication type:
- Letter
50
Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
- Published in:
- 2013
- By:
- Publication type:
- journal article